A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Rifaximin (Primary)
- Indications Bacterial infections; HIV infections; Inflammation
- Focus Biomarker; Therapeutic Use
- 26 Feb 2020 Biomarkers information updated
- 20 Aug 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 28 Jul 2013 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.